Post-Market Review of the Use of Biologics in the Treatment of Severe Chronic Plaque Psoriasis – Public Consultation Process

Page last updated: 28 March 2017

The public consultation process on the Post-Market Review of the Use of Biologics in the Treatment of Severe Chronic Plaque Psoriasis has now closed.

This Review will now include the following two additional medicines:

• secukinumab
• ixekizumab

Sponsors of these two medicines recently added to this group will be invited to provide a submission to the Review. Stakeholders who have previously provided a submission will also be invited to update their submission if required.

Further information on this Review is available on the PBS Website.